SBSB
MRNA icon

Sullivan, Bruyette, Speros & Blaney’s Moderna MRNA Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$176K Buy
1,345
+36
+3% +$5.22K 0.01% 326
2020
Q4 		$137K Buy
+1,309
New +$132K 0.01% 342

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's MRNA Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney increased its Moderna (MRNA) stake by 2.8% in Q1 2021, buying an estimated $5.22K and bringing the position to 1,345 shares worth $176K. The position accounts for 0.01% of the portfolio, ranked #326.

Sullivan, Bruyette, Speros & Blaney first reported a position in MRNA in Q4 2020 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Sullivan, Bruyette, Speros & Blaney held 1,345 shares of Moderna worth $176K as of Q1 2021.
  • Sullivan, Bruyette, Speros & Blaney bought 36 Moderna shares in Q1 2021, an estimated $5.22K.
  • Moderna made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #326 holding.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Moderna in Q4 2020 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.